Stay updated on Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial
Sign up to get notified when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.

Latest updates to the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe site footer revision identifier changes from v3.7.2 to v3.8.0, while the study record history remains unchanged.SummaryDifference0.1%

- Check27 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference0.5%

- Check34 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check40 days agoChange DetectedThe ClinicalTrials.gov site footer now displays revision v3.7.1 instead of v3.7.0.SummaryDifference0.1%

- Check62 days agoChange DetectedThe label for finding contact information was updated from 'Find Contact Information' to 'Find contact information', standardizing capitalization. The revision tag was updated from 'Revision: v3.6.6' to 'Revision: v3.7.0', reflecting a newer page version in the history.SummaryDifference0.2%

- Check76 days agoChange DetectedA new Study Status entry has been added to the Study Record History, and the latest version is labeled 27, reflecting the study's current state within the version history.SummaryDifference0.3%

Stay in the know with updates to Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.